Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,469.99
(
-0.38%
)
News Focus
News Focus
Post# of 808
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

BooDog

Send PM Follow Ignore
Followers 231
Posts 21726
Boards Moderated 1
Alias Born 08/03/2006

BooDog

Re: None

Friday, 07/15/2022 9:45:15 AM

Friday, July 15, 2022 9:45:15 AM

Post# of 808
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $20
6:51 am ET July 1, 2022 (Benzinga) Print
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $18 to $20.

Latest Ratings for LXRX DateFirmActionFromTo

Jan 2021WedbushDowngradesOutperformNeutral Jan 2021JP MorganUpgradesUnderweightNeutral Dec 2020CitigroupUpgradesNeutralBuy

View More Analyst Ratings for LXRX

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BooDog maintains that this is still an excellent swing play bio. At least till their next data set.


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent LXRX News
More LXRX News